Company Profile
Armata Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- ARMP
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.85 USD (+5.19%)
Close
Last updated: October 6, 2026
291M USD
Market cap
Why the stock is moving
As of Oct 6, 2026, ARMP closed up 5.19% at $3.85. No new same-company headline was identified in the current news window.
Company overview
Bacteriophage Therapeutics Company
Armata Pharmaceuticals develops pathogen-specific bacteriophage therapies for serious bacterial infections. Its approach uses naturally occurring viruses that selectively infect and destroy targeted bacteria.
AP-SA02 for Staphylococcus aureus
AP-SA02 is an intravenously administered multi-phage cocktail being developed as an adjunct to antibiotics for complicated Staphylococcus aureus bacteremia. The program is intended for patients with persistent or difficult-to-treat bloodstream infections.
AP-PA02 for Pseudomonas Infections
AP-PA02 is an inhaled phage cocktail targeting Pseudomonas aeruginosa. Clinical development has included patients with cystic fibrosis, with potential expansion into non-cystic-fibrosis bronchiectasis and other chronic pulmonary infections.
Precision Phage Platform
Armata isolates, characterizes, and combines phages according to bacterial targets and resistance profiles. The company maintains manufacturing and analytical capabilities needed to produce complex biologic cocktails for regulated clinical development.
Antibiotic-Adjunct Strategy
The company's therapies are generally designed to be used with standard antibiotics rather than replace them. This combination strategy may improve bacterial clearance while addressing strains that are resistant to conventional drugs.
Future catalysts
- Initiation of the pivotal Phase 3 study of AP-SA02 in complicated Staphylococcus aureus bacteremia in the second half of 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Armata Pharmaceuticals (ARMP)?
Armata Pharmaceuticals (ARMP) most recently closed at 3.85 USD, a +5.19% move versus the previous session.
What is the market cap of Armata Pharmaceuticals (ARMP)?
Armata Pharmaceuticals currently has a market capitalization of 291M USD on BioPharmSignal.
What does Armata Pharmaceuticals do?
Bacteriophage Therapeutics Company Armata Pharmaceuticals develops pathogen-specific bacteriophage therapies for serious bacterial infections. Its approach uses naturally occurring viruses that selectively infect and destroy targeted bacteria. AP-SA02 for Staphylococcus aureus AP-SA02 is an intravenously administered multi-phage cocktail being developed as...
On which exchange is ARMP stock listed?
Armata Pharmaceuticals (ARMP) is associated with NYSE, United States, Biopharma.
What is AP-SA02?
Initiation of the pivotal Phase 3 study of AP-SA02 in complicated Staphylococcus aureus bacteremia in the second half of 2026.
Which conditions is Armata Pharmaceuticals targeting with AP-SA02?
Initiation of the pivotal Phase 3 study of AP-SA02 in complicated Staphylococcus aureus bacteremia in the second half of 2026.
How does Armata Pharmaceuticals describe recent progress with AP-SA02?
Initiation of the pivotal Phase 3 study of AP-SA02 in complicated Staphylococcus aureus bacteremia in the second half of 2026.
What is AP-PA02?
AP-PA02 for Pseudomonas Infections AP-PA02 is an inhaled phage cocktail targeting Pseudomonas aeruginosa.